Saturday, March 2, 2024

CATEGORY

GlaxoSmithKline

New Report Reveals Disparities in Adult Vaccine Access and Uptake Across Global Cities

A new report from the IQVIA Institute for Human Data Science, funded by GSK in collaboration with the Global Coalition on Aging (GCOA), sheds...

GSK Receives Positive CHMP Opinion for Momelotinib to Treat Myelofibrosis Patients with Anemia in the EU

In a significant development, GSK has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

GlaxoSmithKline Reports Strong Q3 2023 Sales Growth and Raises Annual Guidance

Pharmaceutical giant GlaxoSmithKline (GSK) has announced impressive financial results for the third quarter of 2023, showcasing a robust performance driven by various sectors of...

GlaxoSmithKline Reports Robust Q3 2023 Sales Growth, Boosted by Vaccine Success

GlaxoSmithKline (GSK) has announced impressive financial results for Q3 2023, marked by substantial sales and earnings growth, driven by a diverse range of factors....

GSK’s Jemperli Plus Chemotherapy Shows Significant Survival Benefit in Endometrial Cancer Phase III Trial

GSK (GlaxoSmithKline) has announced encouraging results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO Phase III trial evaluating Jemperli (dostarlimab) in combination with standard chemotherapy for...

GlaxoSmithKline’s Arexvy Shows Positive Results in RSV Vaccine Trial for Adults Aged 50-59

GlaxoSmithKline (GSK) has reported encouraging preliminary findings from a Phase III trial evaluating the immune response and safety of its respiratory syncytial virus vaccine,...

GSK Secures Exclusive Rights for Promising Cancer Treatment HS-20089 from Hansoh Pharma

GSK (GlaxoSmithKline) and Hansoh Pharma, a leading Chinese biopharmaceutical company, have announced an exclusive license agreement for HS-20089, an innovative B7-H4 targeted antibody-drug conjugate...

Latest news

Sticky Image